Bispecific Antibodies: The Next Frontier in Targeted Therapies?
"How asymmetric engineering is revolutionizing bispecific antibody design for enhanced precision and reduced side effects."
Therapeutic antibodies have become essential tools in treating various diseases. These antibodies often rely on their Fc region to trigger effector functions, which involve the immune system attacking diseased cells. These effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), are activated when the antibody interacts with immune cells and complement proteins.
Bispecific antibodies represent an innovative class of therapeutics designed to recognize two different targets simultaneously. This dual-targeting approach allows for novel functions that traditional antibodies cannot achieve. However, many therapeutic strategies require these bispecific antibodies to have reduced or silenced effector functions. This is particularly important when the antibody redirects immune cells or engages immunomodulatory targets, where uncontrolled effector activity can lead to unintended side effects.
Traditional methods for reducing effector function have relied on specific antibody subtypes or symmetric mutations in the Fc region. Now, researchers are exploring asymmetric Fc engineering to fine-tune the activity of bispecific antibodies. This involves introducing different mutations on each arm of the Fc region, offering greater control over effector functions and improving the antibody's overall therapeutic profile.
A Dual-Targeting Class on the Rise
Bispecific antibodies are engineered proteins that can simultaneously bind to two different antigens, or two distinct epitopes on the same antigen, whereas naturally occurring antibodies typically target only a single antigen. This dual-binding capability allows them to activate immune cells, disrupt signaling, and regulate immune reactions, which is why they are used chiefly in oncology and immunology to redirect immune cells or block multiple pathways. The class encompasses a variety of structural formats, including antibodies with heterodimerization domains, quadromas, and minimal-size bispecific constructs. Together, these properties position bispecifics as a distinctive and rapidly expanding segment of the therapeutics market.
Engineering and Manufacturing Challenges
The standard approach to building a bispecific antibody is to engineer a single protein that binds two different antigens or epitopes simultaneously, a dual-targeting ability that surpasses the limitations of naturally occurring monoclonal antibodies, whose single-target design becomes restrictive as understanding of disease biology deepens. Functionally, such 'two-target' constructs can interfere with multiple surface receptors or ligands involved in cancer, proliferation, or inflammatory processes. From a manufacturing standpoint, bispecifics expressed and assembled from a single upstream culture require the correct balance and pairing of four different heavy and light chains. Because the increased potential for chain-mispaired species fundamentally challenges downstream purification, ensuring correct chain pairing remains a core production hurdle.
From 1960s Concept to 2014 Approval
The concepts underlying bispecific antibodies were first described as early as the 1960s, but it took more than two decades for the approach to be translated to the clinic. The developmental history is often delineated into five distinct phases that trace the field's gradual technical maturation. A defining milestone came when blinatumomab (Blincyto) was approved by the FDA and EMA in 2014, cementing the viability of the approach. In the most widely used versions, T-cell engagers tether a tumor target to immune cells, transforming resting T cells into potent killers at the tumor site through this direct engagement.
Asymmetric Fc Engineering: A New Approach
A recent study published in Antibodies journal details a novel approach to engineering asymmetric Fc regions in bispecific antibodies. Researchers at Zymeworks Inc. and the National Research Council Canada developed asymmetric Fc mutations that reduce or silence effector functions. This innovative design involves introducing charged mutations in the lower hinge and CH2 domain of the Fc region, creating heterodimeric molecules with distinct properties.
Momentum in the Clinic and the Pipeline
By March 2025, bispecific antibodies had reportedly completed their trek from laboratory concepts to frontline therapies, driven by increasingly sophisticated engineering, targeted clinical programs, and strategic market positioning. Reviews of the field survey preclinical and clinical applications of bispecific-based immunotherapy across solid tumors, hematologic malignancies, and other diseases, including ongoing clinical trials and alternative strategies. The development of bispecific antibody-drug conjugates has further expanded therapeutic potential by combining dual-targeting precision with delivery of cytotoxic payloads to improve efficacy while minimizing toxicity. Taken together, these developments suggest the field is gaining momentum after years of research and development.
The Unresolved Light Chain Problem
A key technical limitation documented in the literature concerns asymmetric bispecific antibodies, where genetic engineering has been used to solve what is described as the 'light chain problem.' While modifications that force heterodimerization of Fc regions address the heavy chain problem, these approaches reportedly still suffer from the light chain problem. In other words, forcing the heavy chains to pair correctly does not by itself guarantee correct pairing of the light chains. According to the source, this residual issue remains a distinct obstacle in the manufacturing of asymmetric bispecific antibodies.
Bispecifics Against Monoclonals, Cocktails, and CAR-T
Compared with conventional monoclonal antibodies, bispecifics differ in structure, mechanism, and production: instead of engaging a single antigen, they carry two recognition specificities within the same molecule. Against antibody cocktails, bispecifics offer the same dual-recognition strategy consolidated into one construct, with neutralization potency against SARS-CoV-2 reflected in their IC50 values. Relative to CAR T-cell therapy, clinicians report that bispecifics produce lower rates of cytokine release syndrome, lower rates of high-grade cytokine release syndrome, and far lower rates of the immunologic adverse event ICANS. These comparisons, along with the reshaping of oncology by T-cell engagers, frame the trade-offs investors and clinicians weigh among bispecifics, ADCs, and CAR-T.
Future Implications
The development of asymmetric Fc engineering represents a significant advancement in the field of bispecific antibodies. By carefully tuning the effector functions, researchers can create more precise and effective immunotherapies. These engineered antibodies hold great promise for treating a wide range of diseases, including cancer and autoimmune disorders. Further studies will be needed to evaluate their clinical potential and optimize their design for specific therapeutic applications.
Standard of Care, with Managed Adverse Events
Bispecific antibodies that engage T cells, along with antibody-drug conjugates and chimeric antigen receptor (CAR) T cells, are widely used standard-of-care therapies that have revolutionized the treatment of lymphoid and plasma cell malignancies. Their defining feature is the ability to bind two targets on two different cells at the same time, which distinguishes them from most antibody drugs in wide use that are limited to latching onto a single antigen on a single cell. Expert opinion holds that the BiTE platform in particular has great potential in the treatment of malignant disease. At the same time, expert consensus recommendations have been developed for managing adverse events related to bispecific antibodies in multiple myeloma, underscoring that clinical benefit comes with defined safety oversight.
Projections, Pipelines, and Competitive Growth
Market forecasts point to substantial growth, although sources differ in scale: one analysis values the global bispecific antibodies market at USD 17.99 billion in 2025 and projects it to reach around USD 603.13 billion by 2035 at a CAGR of 42.08%, while another more modestly projects the humanized bispecific antibodies segment to reach $10.5 billion by 2033. A separate report simply projects a strong CAGR over the 2026–2031 forecast period. Underlying these projections, pipeline trackers count more than 180 companies and over 250 drugs in the bispecific antibody competitive landscape as of 2025. Major players such as Johnson & Johnson and AstraZeneca are cited among the key drivers of this expansion.
Stretching Current Research Processes
Because bispecifics are increasingly used to treat complex diseases, development has moved toward bispecific and multispecific antibodies that demand new combinations of antibody parts as diverse and ingenious as the immune system itself. According to the source, this complexity can challenge current research processes, which are not necessarily built for assembling multiple specificities into a single molecule. The systemic challenge is thus as much organizational as scientific: workflows, platforms, and pipelines must adapt to keep pace with increasingly elaborate molecular designs.
Evidence From Community Practice
Real-world utilization data for bispecific antibodies in relapsed/refractory multiple myeloma in the US community oncology setting show promising results in patient characteristics and uptake, with potential implications for patient outcomes and future decision-making. Clinicians are similarly evaluating real-world use of these agents for patients with R/R multiple myeloma treated outside academic centers, reflecting growing comfort with the class in community practice. Real-world insights are also emerging for relapsed/refractory large B-cell lymphomas, where bispecifics are being examined in everyday care settings. Complementing these clinical datasets, a global pharma organization has used AI-driven social intelligence to compare real-world perceptions of bispecifics against CAR T-cell therapies in the second-line LBCL treatment landscape.